NASDAQ:RGEN - Free Report ) by 61.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 205,883 shares of the biotechnology company's stock after acquiring an additional 78,591 shares during the period. TimesSquare Capital Management LLC owned about 0.37% of Repligen worth $37,018,000 as of its most recent SEC filing.
Get Repligen alerts:
Sign Up
Several other large investors have also recently added to or reduced their stakes in the stock. abrdn plc boosted its stake in Repligen by 1.4% during the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company's stock valued at $934,000 after acquiring an additional 71 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock valued at $45,000 after buying an additional 86 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Repligen by 14.8% during the 3rd quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company's stock valued at $107,000 after purchasing an additional 87 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Repligen by 3.2% during the 3rd quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company's stock valued at $509,000 after acquiring an additional 100 shares during the last quarter. Finally, State of Michigan Retirement System boosted its position in shares of Repligen by 0.8% in the 4th quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $2,239,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Repligen Stock Down 0.4 % NASDAQ RGEN traded down $0.61 during trading hours on Thursday, hitting $164.89. The company's stock had a trading volume of 419,610 shares, compared to its average volume of 536,302. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The company's 50-day simple moving average is $179.23 and its two-hundred day simple moving average is $174.56. The company has a market capitalization of $9.21 billion, a PE ratio of 650.00, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13.
Repligen (NASDAQ:RGEN - Get Free Report ) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million for the quarter, compared to analysts' expectations of $150.06 million. During the same quarter last year, the firm posted $0.64 earnings per share. The firm's revenue for the quarter was down 17.1% compared to the same quarter last year. Research analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.
Insider Buying and Selling at Repligen In related news, CEO Anthony Hunt sold 16,707 shares of the business's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company's stock, valued at approximately $36,575,562.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link . In other news, CEO Anthony Hunt sold 16,707 shares of the company's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares of the company's stock, valued at approximately $36,575,562.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link . Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here . Insiders sold 25,597 shares of company stock worth $5,039,532 in the last quarter. 1.20% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth RGEN has been the subject of a number of research analyst reports. Stifel Nicolaus increased their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a research report on Thursday, February 22nd. JPMorgan Chase & Co. cut their price objective on Repligen from $230.00 to $200.00 and set an "overweight" rating for the company in a research report on Thursday, May 2nd. Finally, KeyCorp upped their price target on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $197.75.
Check Out Our Latest Analysis on Repligen
Repligen Profile (
Free Report )
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report ).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate . These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
